Group 1 - Pediatrix Medical Group reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and up from $0.32 per share a year ago, representing an earnings surprise of 37.84% [1] - The company achieved revenues of $502.36 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.44%, compared to $496.44 million in the same quarter last year [2] - The stock has increased approximately 7.6% since the beginning of the year, outperforming the S&P 500's gain of 4.5% [3] Group 2 - The earnings outlook for Pediatrix Medical Group is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.24 on revenues of $472.5 million, and $1.47 on $1.97 billion in revenues for the current fiscal year [7] - The Medical Services industry, to which Pediatrix belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges for stock performance [8] Group 3 - The company has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] - The current Zacks Rank for Pediatrix Medical Group is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]
Pediatrix Medical Group (MD) Surpasses Q4 Earnings and Revenue Estimates